Public or Private? | GenomeWeb

Public or Private?

Myriad CEO Peter Meldrum wrote into the New York Times in a June 20 letter, to highlight that while the Supreme Court invalidated the company's patent claims of isolated gene sequences, the court upheld several claims on synthetic DNA. In addition, he underscores the importance of diagnostic method patents.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Related Posts

Hidden Away

Biotech Court

Decades in the Making

Impetus to Share

Devil's Deal?

Nature News explores the president's "science legacy."

In PLOS this week: genetic factors associated with facial features, a new mutation that makes individuals more prone to Brugada syndrome, and more.

Nutrigenomic companies offer gene-based diet advice, the Wall Street Journal reports.

Researchers have found a new kind of virus — one that starts out broken up into five parts.